Bórquez Ignacio, Krawczyk Noa, Matthay Ellicott C, Charris Rafael, Dupré Sofía, Mateo Mariel, Carvacho Pablo, Cerdá Magdalena, Castillo-Carniglia Álvaro, Valenzuela Eduardo
Center for Opioid Epidemiology and Policy (COEP), Division of Epidemiology, Department of Population Health, New York University Grossman School of Medicine, New York, NY, USA.
Millennium Nucleus for the Evaluation and Analysis of Drug Policies (nDP), Chile.
Addiction. 2025 Apr;120(4):756-769. doi: 10.1111/add.16731. Epub 2025 Jan 9.
Evidence from high-income countries has linked duration and compliance with treatment for substance use disorders (SUDs) with reductions in substance use and improvements in mental health. Generalizing these findings to other regions like South America, where opioid and injection drug use is uncommon, is not straightforward. We examined if length of time in treatment and compliance with treatment reduced subsequent substance use and presence of psychiatric comorbidities.
Prospective cohort analysis (3 assessments, 18 months) using inverse probability weighting to account for confounding and loss to follow-up.
Outpatient/inpatient programs in Región Metropolitana, Chile.
Individuals initiating publicly funded treatment (n = 399).
Exposures included length of time in (0-3, 4-7, 8 + months, currently in) and compliance with treatment (not completed, completed, currently in) measured in the intermediate assessment (12 months). Primary outcomes were past-month use of primary substance (most problematic) and current psychiatric comorbidities (major depressive episode, panic, anxiety or post-traumatic stress disorders) measured 6 months later (18 months). Secondary outcomes included past month use of alcohol, cannabis, cocaine powder and cocaine paste.
18.3% [95% confidence interval (CI) = 14.7%-22.6%] of individuals participated for 3 or fewer months in treatment and 50.1% (95% CI = 45.2%-55.1%) did not complete their treatment plan at 12 months. Participating for 8 + months in treatment was associated with lower risk of past month use of primary substance at 18 months [vs. 0-3 months, risk ratio (RR) = 0.62, 95% CI = 0.38-1.00] and completion of treatment (vs. not completed, RR = 0.49, 95% CI = 0.30-0.80). Neither participating 8 + months (vs. 0-3 months, RR = 0.83, 95% CI = 0.57-1.22) nor treatment completion (vs. not completed, RR = 1.02, 95% CI = 0.72-1.46) were associated with lower risk of psychiatric comorbidity at 18 months.
Longer time in treatment and compliance with treatment for substance use disorders in Chile appears to be associated with lower risk of substance use but not current comorbid psychiatric conditions 18 months after treatment initiation.
来自高收入国家的证据表明,物质使用障碍(SUDs)治疗的时长及依从性与物质使用的减少及心理健康的改善相关。将这些研究结果推广至南美洲等其他地区并非易事,因为在这些地区阿片类药物和注射吸毒并不常见。我们研究了治疗时长和治疗依从性是否能降低后续的物质使用及精神疾病共病情况。
前瞻性队列分析(3次评估,为期18个月),采用逆概率加权法来处理混杂因素和失访情况。
智利首都大区的门诊/住院项目。
开始接受公共资助治疗的个体(n = 399)。
暴露因素包括中期评估(12个月时)测量的治疗时长(0 - 3、4 - 7、8个月以上、目前仍在治疗)和治疗依从性(未完成、已完成、目前仍在治疗)。主要结局指标是6个月后(18个月时)过去一个月主要物质(问题最大的物质)的使用情况以及当前的精神疾病共病情况(重度抑郁发作症、惊恐症、焦虑症或创伤后应激障碍)。次要结局指标包括过去一个月酒精、大麻、可卡因粉末和可卡因糊剂的使用情况。
18.3%[95%置信区间(CI)= 14.7% - 22.6%]的个体接受治疗3个月或更短时间,50.1%(95% CI = 45.2% - 55.1%)的个体在12个月时未完成治疗计划。治疗8个月以上与18个月时过去一个月主要物质使用风险较低相关[与0 - 3个月相比,风险比(RR)= 0.62,95% CI = 0.38 - 1.00],且与完成治疗相关(与未完成相比,RR = 0.49,95% CI = 0.30 - 0.80)。治疗8个月以上(与0 - 3个月相比,RR = 0.83,95% CI = 0.57 - 1.22)和治疗完成(与未完成相比,RR = 1.02,95% CI = 0.72 - 1.46)均与18个月时精神疾病共病风险较低无关。
在智利,物质使用障碍治疗时间延长及治疗依从性提高似乎与物质使用风险降低相关,但与治疗开始18个月后的当前共病精神状况无关。